LPLance R. Peterson

Lance R. Peterson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lance R. Peterson has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Donna M. Schora

    Department of Laboratory Medicine and Pathology, NorthShore University HealthSystem, Evanston, Illinois, USA

    5 shared publications
  • Parul A. Patel

    Department of Laboratory Medicine and Pathology, NorthShore University HealthSystem, Evanston, Illinois, USA

    5 shared publications
  • Ari Robicsek

    Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL; Division of Infectious Diseases, Department of Medicine, NorthShore University HealthSystem, Evanston, IL; Department of Infection Control, NorthShore University HealthSystem, Evanston, IL

    3 shared publications
  • Becky A. Smith

    Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL; Division of Infectious Diseases, Department of Medicine, NorthShore University HealthSystem, Evanston, IL; Department of Infection Control, NorthShore University HealthSystem, Evanston, IL

    2 shared publications
  • Jennifer L. Beaumont

    Clinical Outcomes Solutions, Tucson, USA

    2 shared publications
  • Kari E. Peterson

    Division of Microbiology, Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, IL

    2 shared publications

Latest Publications

  • Validation of Active Surveillance Testing for Clostridium difficile Colonization Using the cobas Cdiff Test

    by Parul A. Patel, Donna M. Schora, Kamaljit Singh, Lance R. Peterson

    Clostridium difficile infection (CDI) is not declining in the United States. Nucleic acid amplification tests (NAAT) are used as part of active surveillance testing programs to prevent health care-associated infection. The objective of this study was to validate the cobas Cdiff Test on the cobas 4800 System (cobas) within a four-hospital system using prospectively collected perirectal swabs from asymptomatic patients at admission and during monthly intensive care unit (ICU) screening in an infection control CDI reduction program. Performance of the cobas was compared to that of toxigenic culture. Each positive cobas sample and the next following negative patient swab were cultured. The study design gave 273 samples processed by both cobas (137 positive and 136 negative) and culture (one negative swab was not cultured). Discrepant analysis was performed using a second NAAT, the Xpert C. difficile Epi test (Xpert). This strategy was compared to a medical record review for antibiotic receipt that would inhibit growth of C. difficile in colonic stool. None of the cobas-negative samples were culture positive. The cobas positive predictive value was 75.2% (95% confidence interval [CI], 66.9% to 82%) and positive percent agreement was 100% (95% CI, 96.0% to 100%). Overall agreement between cobas and direct toxigenic culture was 87.6% (95% CI, 83.1% to 91%). For the cobas-positive/culture-negative (discrepant) samples, 7 Xpert-positive samples were from patients receiving inhibitory antimicrobials; only 4 of 23 Xpert-negative samples received these agents ( P = 0.00006). Our results support use of the cobas as a reliable assay for an active surveillance testing program to detect asymptomatic carriers of toxigenic C. difficile .


  • Contact Precautions for Multidrug-Resistant Organisms

    by Lance R. Peterson

    To the Editor The Viewpoint by Dr Morgan and colleagues1 raised questions regarding contact precautions for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), stating that contact precautions “may pose an opportunity cost to infection control” and that “hospitals should reconsider best use of contact precautions for endemic MRSA and VRE.” Importantly, available evidence supports an opposing position.


  • Open Access

    Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples

    by Lance R. Peterson, Stephen A. Young, Thomas E. Davis, Zi-Xuam Wang, John Duncan, Christopher Noutsios, Oliver Liesenfeld, John C. Osiecki, Michael A. Lewinski

    Nucleic acid amplification tests (NAATs) are reliable tools for the detection of toxigenicClostridium difficilefrom unformed (liquid or soft) stool samples. The objective of this study was to evaluate performance of the cobas Cdiff test on the cobas 4800 system using prospectively collected stool specimens from patients suspected of havingC. difficileinfection (CDI). The performance of the cobas Cdiff test was compared to the results of combined direct and broth-enriched toxigenic culture methods in a large, multicenter clinical trial. Additional discrepancy analysis was performed by using the XpertC. difficileEpi test. Sample storage was evaluated by using contrived and fresh samples before and after storage at −20°C. Testing was performed on samples from 683 subjects (306 males and 377 females); 113 (16.5%) of 683 subjects were positive for toxigenicC. difficileby direct toxigenic culture, and 141 of 682 subjects were positive by using the combined direct and enriched toxigenic culture method (reference method), for a prevalence rate of 20.7%. The sensitivity and specificity of the cobas Cdiff test compared to the combined direct and enriched culture method were 92.9% (131/141; 95% confidence interval [CI], 87.4% to 96.1%) and 98.7% (534/541; 95% CI, 97.4% to 99.4%), respectively. Discrepancy analysis using results for retested samples from a second NAAT (Xpert C. difficile/Epi test; Cepheid, Sunnyvale, CA) found no false-negative and 4 false-positive cobas Cdiff test results. There was no difference in positive and negative results in comparisons of fresh and stored samples. These results support the use of the cobas Cdiff test as a robust aid in the diagnosis of CDI.


  • Open Access

    Antimicrobial Stewardship Lessons From Mupirocin Use and Resistance in Methicillin-Resitant Staphylococcus Aureus

    by Lance R. Peterson, Noelle I. Samia, Andrew M Skinner, Amit Chopra, Becky Smith

    The quantitative relationship between antimicrobial agent consumption and rise or fall of antibiotic resistance has rarely been studied. We began all admission surveillance testing for methicillin-resistant Staphylococcus aureus (MRSA) in August 2005 with subsequent contact isolation and decolonization using nasally applied mupirocin ointment for those colonized. In October 2012, we discontinued decolonization of medical (nonsurgical service) patients. We conducted a retrospective study from 2007 through 2014 of 445680 patients; 35235 were assessed because of mupirocin therapy and positive test results for MRSA. We collected data on those patients receiving 2% mupirocin ointment for decolonization to determine the defined daily doses (DDDs). A nonparametric regression technique was used to quantitate the effect of mupirocin consumption on drug resistance in MRSA. Using regressive modeling, we found that, when consumption was consistently >25 DDD/1000 patient-days, there was a statistically significant increase in mupirocin resistance with a correlating positive rate of change. When consumption was ≤25 DDD/1000 patient-days, there was a statistically significant decrease in mupirocin resistance with a correlating negative rate of change. The scatter plot of fitted versus observed mupirocin resistance values showed an R2 value of 0.89—a high correlation between mupirocin use and resistance. Use of the antimicrobial agent mupirocin for decolonization had a threshold of approximately 25 DDD/1000 patient-days that separated a rise and fall of resistance within the acute-care setting. This has implications for how widely mupirocin can be used for decolonization, as well as for setting consumption thresholds when prescribing antimicrobials as part of stewardship programs.


  • Reduction of methicillin-resistant Staphylococcus aureus infection in long-term care is possible while maintaining patient socialization: A prospective randomized clinical trial

    by Lance R. Peterson, Susan Boehm, Jennifer L. Beaumont, Parul A. Patel, Donna M. Schora, Kari E. Peterson, Deborah Burdsall, Carolyn Hines, Maureen Fausone, Ari Robicsek, et al.


  • Open Access

    Methicillin-Resistant Staphylococcus aureus Control in the 21st Century: Laboratory Involvement Affecting Disease Impact and Economic Benefit from Large Population Studies

    by Lance R. Peterson, Donna M. Schora

    Methicillin-resistant Staphylococcus aureus infection is a global healthcare problem. Large studies (e.g., >25,000 patients) show active surveillance testing (AST) followed by contact precautions for positive patients an effective MRSA disease control approach. The clinical laboratory will be asked to select what AST method(s) to use and provide data monitoring outcome of infection prevention interventions. This minireview summarizes evidence for MRSA disease control, the involvement of the laboratory, and provides examples of how to undertake a program cost analysis. Healthcare organizations with total MRSA clinical infections >.3/1,000 patient days, or blood-stream infection >.03/1,000 patient days should implement a MRSA control plan.


  • Nonimpact of Decolonization as an Adjunctive Measure to Contact Precautions for the Control of Methicillin-Resistant Staphylococcus aureus Transmission in Acute Care

    by Lance R. Peterson, Marc O. Wright, Jennifer L. Beaumont, Vanida Komutanon, Parul A. Patel, Donna M. Schora, Bryan H. Schmitt, Ari Robicsek

    This was an observational study comparing methicillin-resistant Staphylococcus aureus (MRSA) transmission with no decolonization of medical patients to required decolonization of all MRSA carriers during two consecutive periods: baseline with no decolonization of medical patients (16 months) and universal MRSA carrier decolonization (13 months). The setting was a one-hospital, 156-bed facility with 9,200 annual admissions. Regression models were used to compare rates of MRSA acquisition. The chi-square test was used to compare event frequencies. We used rates of MRSA clinical disease as an outcome monitor of the program. Analysis was done on 15,666 patients who had admission and discharge tests; 27.9% of inpatient days were occupied by a MRSA-positive patient (colonized patient-days) who received decolonization while hospitalized during the baseline period (this 27.9% represented those who had planned surgery) compared to 76.0% during the intervention period ( P < 0.0001). The rate of MRSA transmission was 97 events (1.0%) for 9,415 admissions (2.0 transmission events/1,000 patient-days) during baseline and was 87 (1.4%) for 6,251 admissions (2.7 transmission events/1,000 patient-days) during intervention ( P = 0.06; rate ratio, 0.74; 95% confidence interval [CI], 0.55 to 1.00). The MRSA nosocomial clinical disease rate was 5.9 infections/10,000 patient-days in the baseline period and was 7.2 infections/10,000 patient-days for the intervention period (rate ratio, 0.82; 95% CI, 0.46 to 1.45; P = 0.49). Decolonization of MRSA patients does not add benefit when contact precautions are used for patients colonized with MRSA in acute (hospital) care.


  • Open Access

    Evaluation of Multiple Real-Time PCR Tests on Nasal Samples in a Large MRSA Surveillance Program

    by Parul A. Patel, Ari Robicsek, Althea Grayes, Donna M. Schora, Kari E. Peterson, Mt(Ascp) Marc O. Wright, Lance R. Peterson

    We evaluated the LightCycler MRSA Advanced Test (Roche Molecular Diagnostics, Pleasanton, CA), the BD MAX MRSA assay (Becton Dickinson, Franklin Lakes, NJ), and the Xpert MRSA assay (Cepheid, Sunnyvale, CA) on nasal samples using the same population. Admission and discharge nasal swabs were collected from inpatients using a double-headed swab. One swab was plated onto CHROMagar MRSA (CMA; Becton Dickinson, Sparks, MD) and then broken off into tryptic soy broth (TSB) for enrichment. TSB was incubated for 24 hours and then plated to CMA. The molecular tests were performed on the second swab. We analyzed the cost benefit of testing to evaluate what parameters affect hospital resources. A total of 27,647 specimens were enrolled. The sensitivity/specificity was 98.3%/98.9% for the LightCycler MRSA Advanced Test and 95.7%/98.8% for the Xpert MRSA assay, but the difference was not significant. The positive predictive value was 86.7% for the LightCycler MRSA Advanced Test, 82.7% for the Xpert MRSA assay (P > .1), and 72.2% and for the BD MAX MRSA test (P < .001 compared with the LightCycler MRSA Advanced Test). All three assays were cost-effective, with the LightCycler MRSA Advanced Test having the highest economic return. Our results suggest that the performance of the three commercial assays is similar. When assessing economic cost benefit of methicillin-resistant Staphylococcus aureus screening, the two measures with the most impact are the cost of the test and the specificity of the assay results.


  • Open Access

    Nonutility of Catheter Tip Cultures for the Diagnosis of Central Line-Associated Bloodstream Infection

    by Lance R. Peterson, Becky A. Smith

    To the Editor—We read with interest the study by Erb and colleagues, who elegantly assessed the laboratory approach for confirmation of catheter-related bacteremia [1]. They prospectively assessed the classic semiquantitative roll-plate culture and compared results to agitation by sonication/vortexing of the catheter in liquid, followed by plating and incubation [2, 3]. This is an important investigation, as the Infectious Diseases Society of America (IDSA) guideline for managing central line–associated bloodstream infection (CLABSI) recommends use of catheter tip cultures for CLABSI in 6 of the 10 diagnostic recommendations, with ratings ranging from AI to BIII [4]. An early meta-analysis found quantitative culture to be optimal over qualitative culture [5], and 2 prior European studies demonstrated no difference between these techniques [6, 7], as did the current investigation. However, we believe the results of this well-done study raise a serious question regarding the utility of this test for the diagnosis of CLABSI.


  • Open Access

    Active Surveillance and Decolonization Without Isolation Is Effective in Preventing Methicillin-Resistant Staphylococcus aureus Transmission in the Psychiatry Units

    by Sanchita Das, Maureen Harazin, Marc Oliver Wright, Irene Dusich, Ari Robicsek, Lance R. Peterson

    Background. Control of methicillin-resistant Staphylococcus aureus (MRSA) is difficult in select populations. We used molecular typing to study the effect of universal surveillance and decolonization of carriers, without isolation, on MRSA transmission in a specialized unit. Methods. Patients admitted to the unit were screened for nasal MRSA at admission and discharge. Those who acquired MRSA during their stay were identified and linked to carriers with shared time in unit. Molecular typing of isolates was performed to identify transmission. Results. Of 3285 admissions, 82% were tested for MRSA nasal carriage; the discharge screening compliance was 64.7%. Admission prevalence was 2.3% among patients screened, and 7 (0.42%) acquired nasal MRSA during their stay. All patients who acquired MRSA shared time in the unit with a colonized patient. There were 3.9 MRSA acquisitions per 1000 at-risk days. Isolates from 5 patients that acquired MRSA during their stay as well as their potential donors (11 donor: recipient patient pairs) were available for typing. Pulsed-field gel electrophoresis matched 1 acquisition isolate to a colonized patient isolate. There were no MRSA infections during the study period. Conclusions. Despite less than perfect nasal screening compliance and exemption from traditional isolation precautions, acquisition of MRSA was 0.42% in this patient population over a course of 4.75 years, including a single case of acquisition, genetically similar to a known potential donor source. Screening for MRSA colonization and decolonizing of carriers was sufficient in reducing transmission in this vulnerable population.